Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/PTSD

Ketamine for PTSD

60 papers and 32 clinical trials exploring ketamine as a treatment for ptsd.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication354 million people suffering from PTSD globally.

PTSD

Posttraumatic stress disorder (PTSD) is a significant mental health challenge affecting over 354 million individuals globally. Psychedelics, particularly MDMA and psilocybin, are emerging as promising therapeutic options, offering new avenues for treatment through innovative psychotherapeutic interventions.

Full PTSD profile

Academic Research

60 papers
Open Accessindividual

Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)

This open-label trial (n=25) found that six weeks of low-dose oral ketamine treatment for PTSD was associated with small but significant decreases in both BDNF and VEGF-A blood biomarkers, which were positively correlated with each other, suggesting these two proteins may interact as part of the biological mechanism behind ketamine's effects on PTSD symptoms.

Published
March 16, 2026
Journal
Psychopharmacology
Authors
Quigley, B. L., Orr, E., Kafka, S., Hajishafiee, M., Bouças, A. P., Wellington, N., Dutton, M., Jones, M., Randall, F., Lagopoulos, J., Can, A. T., Hermens, D. F.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallindividual

Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics

This rat study found that zalsupindole (third-generation psychedelic) produced robust effects on structural and functional neuroplasticity in the prefrontal cortex as well as sustained antidepressant-like responses comparable to or greater than those of ketamine, psilocybin, and DMT, despite lacking any of the acute cellular and behavioural characteristics of hallucinogenic or dissociative compounds.

Published
October 13, 2025
Journal
ACS Chemical Neuroscience
Authors
Agrawal, R., Gillie, D., Mungenast, A., Chytil, M., Engel, S., Wu, M. C., Rasmussen, K., Salinas, E., Olson, D. E.
Paywallindividual

Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample

This observational study (n=202, 470, and 624) compares ketamine alone (KET) to ketamine combined with psychotherapy (KET+PSY) (35mg x 6) for depression and PTSD. Both treatments led to substantial symptom improvements, but no significant differences were found between groups. Exploratory analyses suggest younger females may benefit more from combined treatment, while older males may do better with ketamine alone.

Published
July 1, 2025
Journal
Journal of Affective Disorders
Authors
Moore, T. M., Walker, K., Tung, E., Teed, A. R., Hell, F., Kinreich, S., Jung, R., Abdel, F., Hanson, R. W., Ahmed, S. S.
Open Accessindividual

Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging

This preprint open-label study (n=20) examines the effects of ketamine infusions (35mg/70kg, 6x) on biological ageing markers in individuals with depression (MDD) or PTSD. It finds reductions in epigenetic age as measured by OMICmAge, GrimAge V2, and PhenoAge biomarkers, as well as significant changes in Epigenetic Biomarker Proxies (EBPs) and surrogate protein markers following a 2-3 week treatment course. The study also reports expected decreases in depression and PTSD scores as measured by PHQ-9 and PCL-5.

Published
September 11, 2024
Journal
MedRvix
Authors
Dawson, K., May, A., Carangan, J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Perkins, N., Mendez, T. L., Smith, R., Dawson, M., Mallin, M., Higgins-Chen, A. T., Dwaraka, V. B.
Paywallindividual

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

This retrospective observational cohort study (n=966 esketamine initiators, n=39,219 controls) examines factors influencing esketamine initiation and continuation for treatment-resistant depression (TRD). Initiators resided closer to treatment centres, with initiation rates decreasing significantly with distance. Factors associated with increased initiation included posttraumatic stress disorder, suicidal ideation, and male sex, while Medicaid, substance use disorder, older age, and greater distance were associated with lower initiation rates.

Published
May 6, 2024
Journal
Journal of Clinical Psychiatry
Authors
Joshi, K., Liberman, J. N., Parab, P., Darer, J. D., Harding, L.

Clinical Trials

32 trials
Not yet recruitingPhase NA

Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study

This prospective observational pilot study (n=5) will assess whether continuous wearable physiological monitoring can characterise an intra-sessional autonomic arc during ketamine-assisted therapy in adults with post-traumatic stress disorder (PTSD). It will evaluate the feasibility of detecting a consistent autonomic trajectory, using continuous heart rate variability (HRV) and electrodermal activity (EDA) data collected during independently arranged ketamine sessions. Participants aged 19 years or older with confirmed PTSD will wear an EmbracePlus wrist-worn biosensor across a 3–7 day pre-session baseline period, the full ketamine-assisted therapy session, and 3–5 day follow-up monitoring windows at 1, 2 and 4 weeks after the session. The study also includes a structured pre-session interview within 48 hours before treatment and a structured post-session interview within 4 hours after session end, including administration of the Post-Session Subjective Integration Scale. Ketamine is administered solely by the participant’s licensed treating provider, and no drug is given by the researcher. The primary outcome is intra-sessional autonomic arc trajectory characterisation during the ketamine session, with sessions showing EDA channel loss exceeding 15% of the recording window excluded from primary analysis.

Started
July 15, 2026
Type
observational
Blinding
none
Randomized
No
Registry ID
NCT07614581
Not yet recruitingPhase II

KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury

This Phase II, single-group trial (n=12) will assess the safety and tolerability of ketamine-assisted psychotherapy (KAP) in adults aged 18 to 65 years with burn injuries and acute stress symptoms. Participants will receive KAP after screening positive for acute stress symptoms before discharge, with the study focused on treatment-related adverse events and feasibility in this burn population. All participants will be assigned to the same intervention package, beginning with a preparatory psychotherapy session, followed by a 2.5–3 hour ketamine-assisted psychotherapy session in which ketamine is given intramuscularly at 0.5 mg/kg and may be titrated up to 1.0 mg/kg to a maximum of 60 mg according to patient response. A second 2.5–3 hour KAP session is also planned, and an integration session with a trained psychotherapist will be held after the second ketamine administration. Safety outcomes will be tracked from baseline through 6 months after treatment, with follow-up assessments at 1, 3 and 6 months.

Started
April 1, 2026
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07563296
Not yet recruitingPhase I/II

Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD

Open-label, randomised, parallel pilot RCT (n=30) comparing ketamine (0.5 mg/kg IV x4 over 2 weeks) plus MBCT versus MBCT alone for adults with comorbid chronic pain and PTSD.

Started
October 1, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT07009158
Not yet recruitingPhase I/II

Ketamine Plus Exposure Therapy For Post-Traumatic Stress Disorder (PTSD)– Open Label Pilot Study Targeting Anxiety

This open-label Phase I/II trial (n=12) will study the effects of oral ketamine (beginning at 35 mg/70 kg and increasing to 140 mg/70 kg) in combination with prolonged exposure therapy for the treatment of post-traumatic stress disorder (PTSD).

Started
July 31, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12625000722493p
Temporarily not availablePhase II

Department of Defense PTSD Adaptive Platform Trial – Intervention D – SLS-002

This Phase II randomised, quadruple-blind, placebo-controlled trial (n=200) will assess the safety and efficacy of intranasal SLS-002 (ketamine, 78mg) for post-traumatic stress disorder (PTSD) in active-duty service members and veterans.

Started
June 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06816433
RecruitingPhase II

Ketamine, SGB and Combination Treatment for TBI

This randomised, double-blind, placebo-controlled trial (n=175) will investigate the efficacy of stellate ganglion block (SGB) and ketamine infusion, both separately and in combination, in treating PTSD and TBI-associated headache.

Started
February 15, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06608277

Explore further

Search all Ketamine papers Search all PTSD trials Full Ketamine profile Full PTSD profile